| Methods |
4‐week single‐blind placebo washout; inclusion criteria= sitting DBP >/= 95 mm Hg after washout; 12‐week double‐blind treatment, forced titration (dose doubled) every 4 weeks starting at 20 mg daily |
| Participants |
Quinapril once daily: n=91(64 males,27 females); median age=49 years; baseline SBP=163 mm Hg, DBP=107 mm Hg;
Quinapril twice daily: n=90(61 males,29 females); median age=51 years; baseline SBP=164 mm Hg, DBP=106 mm Hg;
Placebo: n=89(56 males,33 females); median age=52 years; baseline SBP=162 mm Hg, DBP=105 mm Hg |
| Interventions |
Quinapril 20, 40, 80 mg once daily (morning administration of active drug);
Quinapril 20, 40, 80 mg twice daily (2 capsules taken 12 h apart);
Placebo |
| Outcomes |
Mean change from baseline in trough sitting SBP/DBP using mercury sphygmomanometer;
WDAE |
| Notes |
Used week 4 BP data only; BP change and SE of change reported, endpoint BP and SD not reported, calculated SD of change from N and change SE; BP data from Table III, p. 375; Jadad score=3; funding source= not reported |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
